PicoCare Majesty: Complete Buyer's Guide

PicoCare Majesty's core FDA-filed platform uses two native wavelengths: 1064nm and frequency-doubled 532nm. The system is designed primarily for picosecond photoacoustic treatment of tattoos and pigmented lesions.

Market materials may reference 595nm and 660nm capability, but these are accessory dye-handpiece wavelengths rather than native laser sources and are not named in the current FDA wavelength schedule. Confirm the exact handpieces and labeling included in the quote.

PicoCare Majesty has inconsistent published pulse-duration figures that buyers should reconcile before purchase. The executive profile reports 275–300ps in comparison data and 300–400ps in performance testing, while commercial materials may state 250ps at 1064nm and 190ps at 532nm.

For purchasing, do not treat the shortest commercial figure as the sole specification. Ask for the exact model's current FDA documentation, serial-specific output testing and written confirmation of the delivered pulse specification.

The Majesty ecosystem can include microlens-array (MLA) and diffractive optical element (DOE) delivery. These options can broaden treatment geometry beyond standard zoom delivery.

Do not assume every new or pre-owned unit includes MLA/DOE handpieces. Package completeness can materially affect clinical breadth and resale value.

The strongest documented U.S. use case is pigment-focused treatment: multicolor tattoo removal and benign pigmented lesions within the cleared labeling and defined Fitzpatrick skin-type ranges.

International and commercial materials may also promote scar, pore and skin-rejuvenation applications. Those claims should not be presented as explicit U.S. FDA indications unless the exact configuration's current labeling supports them.

Wontech's original PicoCare entered the U.S. regulatory record in 2017. The PicoCare Family update cleared in 2018, and the PicoCare Majesty model received its own clearance on January 7, 2022. A later direct Majesty clearance was issued June 24, 2024 and directly names PICOCAREMAJESTY.

• Current direct FDA record identifies PICOCAREMAJESTY.
• Current cleared indications include tattoo removal and benign pigmented lesions, subject to the exact labeling and skin-type parameters.
• Commercial claims for scars, pores and rejuvenation should be verified separately and should not be treated as automatically FDA-cleared indications.

• Current-generation 1064/532nm picosecond Nd:YAG platform with direct 2024 FDA clearance.
• Flexible 2–10mm zoom spot range and operation up to 10Hz.
• Broad handpiece ecosystem with zoom, collimated, MLA and DOE options when included.
• Strong core use case for multicolor tattoos and benign pigmented lesions.
• Optional fractional optics can expand treatment geometry.
• Active Wontech platform with ongoing commercial promotion.

The most important purchasing issue is documentation consistency. FDA-filed pulse-duration figures do not align cleanly with commercial 250ps/190ps claims, so buyers should request current labeling and serial-specific output verification.

Also confirm whether the quote includes MLA, DOE, collimated and dye handpieces. Accessory 595/660nm wavelengths are not native sources, and incomplete accessory packages can reduce clinical breadth and resale value.

Finally, confirm the legal seller, importer, servicing entity, training, parts availability and local service response before signing.

Warranty terms are not publicly standardized in the executive profile. Do not assume a universal one-year package. Obtain the exact written warranty covering the source, articulated arm, optics, handpieces, parts, labor, travel and exclusions, and confirm who is legally responsible for service in your market.